global-vaccines-2017-scientifictracks-abstracts

Page 41

Notes:

allied

academies

Ann Clin Trials Vaccines Res. 2017 | Volume 1 Issue 2

Global Vaccines & Vaccination Summit & B2B

November 01-02, 2017 | Toronto, Canada

B. subtilis

spores as mucosal adjuvants

Veronica Donato

National University of Rosario, Argentina

. subtilis

spores have received growing attention because

of their potential in biotechnology, including vaccine

development. There are only a few studies using these

probiotic bacteria as a vaccine delivery system or as an

adjuvant itself. For this reason, with my lab team, I decided

to study

B. subtilis

spores as a potential candidate to solve

some of the problems of current vaccines such as the need of

refrigeration systems, needles and syringes and booster dose.

I will present some of our data and a review of what is known

about this probiotic bacteria that can help us improving the

inmunization world.

Speaker Biography

She is a Postdoctoral fellow National University of Rosario. School of Biochemistry.

CONICET. Molecular Microbiology Lab. Mentor: Roberto Grau, PhD C. elegans and

Bacillus subtilis. Studies on host-bacteria interactions: aging, gut, inmune and nervous

system. Neurobiology. PDTS38 CONICET Projects. My postdoctoral research focused

on studing the microbiota effects in C. elegans gut, inmune and nervous systems.

Moreover, my project studied the effects of biofilm proficiency, nitric oxide and

bacterial quorum sensing molecules in C. elegans aging process